Immutep announces results from Phase IIb trial of TACTI-003

Immutep (IMMP) announces an excellent median Overall Survival, OS, of 17.6 months has been achieved in Cohort B of the TACTI-003 Phase IIb trial. This part of the Phase II study evaluates eftilagimod alfa in combination with MSD’s (MRK) anti-PD-1 therapy KEYTRUDA as first line therapy in recurrent/metastatic head and neck squamous cell carcinoma patients with PD-L1 expression below 1. The mature 17.6-months median OS in evaluable patients with a data cut-off of 31 March 2025 compares favourably to historical results from the two current standard-of-care approaches for 1L HNSCC patients with CPS less than1 including 10.7-months from cetuximab + chemotherapy and 11.3-months from anti-PD-1 therapy + chemotherapy, as well as 7.9-months from anti-PD-1 monotherapy. Patients with CPS less than1 in 1L HNSCC represent a treatment population with high unmet medical need. Up to 20% of 1L HNSCC patients have CPS less than1 and despite immunotherapy’s progress in fighting cancer, anti-PD-1 therapy alone is only approved for patients who express PD-L1. Additionally, all available treatment options for patients with PD-L1 CPS less than1 include chemotherapy.